Drug Trial Radar · NCT06669403
OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
26
Planned (sponsor's estimate)
Start
Mar 9, 2026
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Op-T LLCIndustry
- Sponsor type
- Industry
- First posted
- Nov 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
OPT101-100-40 is a multicenter, randomized, placebo-controlled, multiple-ascending-dose, sequential-group, investigator- and participant-blinded, sponsor-unblinded, study of OPT101 vs placebo when administered for up to 4 days to patients admitted to the hospital for treatment of Community Acquired Pneumonia (CAP) with sepsis. This study will be performed in patients with Community Acquired Pneumonia (CAP) with Sepsis, who are 18 years or older to evaluate the safety and tolerability of OPT101 in a population with elevated levels of pathologic CD40.
Conditions
- Sepsis
- Community Acquired Pneumonia (CAP)
Interventions
OPT101Drug
OPT101, is a 15-mer peptide derived from the sequence of mouse CD40L and was designed to target CD40-mediated inflammation. On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.
PlaceboOther
0.9% Sodium Chloride Injection USP, Placebo. On the day of administration, a 50mL IV bag containing saline (0.9% Sodium Chloride Injection USP) which will serve as the placebo will be administered via intravenous (IV) infusion over 120 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs)Time frame: 30 days
- Incidence of serious adverse events (SAEs)Time frame: 30 days
- Incidence of TEAEs leading to study drug discontinuationTime frame: 30 days
- Incidence and characteristics of presumed infusion reactionsTime frame: 30 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Denver Health and Hospital Authority
Denver, Colorado · Not yet recruiting
Westchester Medical Center
Valhalla, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.